ClinicalTrials.gg
RecruitingNCT07294508Updated Mar 20, 2026

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

A Phase 2/3 interventional study of HLX87 + HLX22 and HLX87 + Pertuzumab in HER2 + Breast Cancer, sponsored by Shanghai Henlius Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
706
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Breast Neoplasms by Fosun Pharma — 9 open to participants now, 10 under way, 4 of them phase 3. Breast Neoplasms · Fosun Pharma.

Planned enrollment
3rd of 13
706 · median 180
Started
2026
with 5 others
Phase 2/3
2 of 13
2 open now
Registered
8th of 13
by date

Among the 13 studies in Breast Neoplasms by Fosun Pharma, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2026, is one of 2 in phase 2/3, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 13 studies in Breast Neoplasms by Fosun Pharma are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Breast Neoplasms by Fosun Pharma, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer

Read the detailed description

The study consists of two stages Stage I is an open-label, multicenter, randomized, parallel-controlled phase II clinical study, and its primary objective is to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer based on ORR and PFS results.

Stage II is an open-label, multicenter, randomized, parallel-controlled phase III clinical study, and its primary objective is to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer based on PFS results.

03

Conditions studied

  • HER2 + Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Have a full understanding of the study content, and sign the form (ICF); 2. Aged ≥ 18 years at the time of signing the ICF, male or female; 3. Histopathologically confirmed breast cancer that meets the following criteria:

    1. Advanced or breast cancer.
    2. -positive as determined by the central laboratory, defined as IHC 3+, or IHC 2+ and ISH+.
    3. Positive or negative for hormone receptor HR (including estrogen receptor [ER] and progesterone receptor [PgR]) as determined by the central laboratory 4. No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer (1 line of endocrine therapy is allowed).

    5. At least one as assessed by central imaging according to v1.1.

    7. performance status score within 7 days prior to the first dose of study drugs: 0-1.

    8. ≥ 12 weeks. 9. Adequate organ functions

Exclusion criteria

Exclusion Criteria:

  • 1. History of a second within 3 years prior to signing the ICF. 2. Previous use of doxorubicin with a concentration of > 360 mg/m2 (or equivalent).

    3. Prior treatment with ADCs including exatecan derivatives that contain topoisomerase I inhibitors.

    4. Uncontrolled or significant cardiovascular diseases 5. Cerebrovascular accidents within 6 months prior to the first dose of study drugs.

    6. ILD/pneumonitis, or suspected ILD/pneumonitis or lung-specific intercurrent illness .

    7. Active infection . 8. Presence of spinal cord compression or clinically symptomatic central nervous system .

    9. Residual toxicity from previous anti-tumor therapy that has not resolved to Grade ≤ 1 as per V6.0 or baseline level (except for alopecia).

    10. Presence of active tuberculosis. 11. Have received treatment with within 30 days prior to the first dose of study drugs.

    12. Known history of severe allergic reaction to macromolecular protein preparations, to the ingredient of the products, or severe hypersensitivity to any of the study drugs.

    13. Known history of abuse of psychotropic drugs or drug addiction. 14. Pregnant or lactating women.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
706 participants (estimated)

Study arms

  • Experimental
    HLX87+ HLX22

    Patients will receive the treatment once every 3 weeks (Q3W) until progressive disease (PD) , initiation of new anti-tumor therapy, death, intolerable toxicity, withdrawal of informed consent, or end of the study (whichever occurs first).

    Drug: HLX87 + HLX22

  • Experimental
    HLX87+ Pertuzumab

    atients will receive the treatment once every 3 weeks (Q3W) until progressive disease (PD) , initiation of new anti-tumor therapy, death, intolerable toxicity, withdrawal of informed consent, or end of the study (whichever occurs first).

    Drug: HLX87 + Pertuzumab

  • Active comparator
    T-Dxd + Pertuzumab

    Patients will receive the treatment once every 3 weeks (Q3W) until progressive disease (PD) , initiation of new anti-tumor therapy, death, intolerable toxicity, withdrawal of informed consent, or end of the study (whichever occurs first).

    Drug: T-Dxd + Pertuzumab

  • Active comparator
    THP

    Patients will receive the treatment once every 3 weeks (Q3W) until progressive disease (PD) , initiation of new anti-tumor therapy, death, intolerable toxicity, withdrawal of informed consent, or end of the study (whichever occurs first).

    Drug: THP

Interventions

  • DrugHLX87 + HLX22

    Drug page: Dulpatatug

    HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2 .

  • DrugHLX87 + Pertuzumab

    Drug page: Pertuzumab

    HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan

  • DrugT-Dxd + Pertuzumab

    Drug pages: Trastuzumab deruxtecan · Pertuzumab

    T-Dxd is a HER2-targeted ADC

  • DrugTHP

    Pertuzumab+ Trastuzumab+Docetaxel

This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) (assessed by the blinded independent central review [BICR] as per RECIST v1.1)

    Time frame: up to 26 months

  2. Progression-free survival (PFS) (assessed by BICR as per RECIST v1.1)

    Time frame: up to 37 months

Secondary outcomes

  1. ● ORR (assessed by the investigator as per RECIST v1.1)

    Time frame: up to 26 months

  2. ● PFS (assessed by the investigator as per RECIST v1.1)

    Time frame: up to 37 months

  3. Second progression-free survival (PFS2)

    Time frame: up to 37 months

  4. Overall survival (OS)

    Time frame: up to 37 months

  5. Incidence and severity of adverse events (AEs)

    severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 6.0

    Time frame: up to 37 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2028, 22 months after the start.

Of 56 phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Dec 19, 2025
StartActual
Feb 27, 2026
Primary completionEst.
Jan 15, 2028
CompletionEst.
Dec 30, 2030
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07294508
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Feb 27, 2026
Primary completion
Jan 15, 2028 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Mar 20, 2026

Study contacts

Maoqing Fu, Dr
Contact
Maoqing_fu@henlius.com
021-33395800
Ma
Contact
Mafei@163.com
01067781331
Fei Ma, Dr
principal investigator · Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulpatatug

Start the discussion